Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
Carcinoembryonic antigen glypican-3 (GPC3) is expressed by >40% of ovarian clear cell carcinoma (CCC) and is a promising immunotherapeutic target. We previously reported the safety of and immunological and clinical responses to a GPC3-derived peptide vaccine in a phase I clinical trial of patient...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185885/ |